表紙
市場調査レポート

インスリン抵抗性:パイプライン分析

Insulin Resistance - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 245980
出版日 ページ情報 英文 62 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
インスリン抵抗性:パイプライン分析 Insulin Resistance - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 62 Pages
概要

インスリン抵抗性(IR)は、体の細胞がインスリンの効果に耐性を示す状態です。倦怠感、空腹、集中力の欠如、高血圧などの症状が見られます。素因として、肥満や高血圧が挙げられます。

当レポートでは、インスリン抵抗性に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

インスリン抵抗性の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • AUS Bio Limited
  • Genfit SA
  • GlaxoSmithKline Plc
  • Hadasit Medical Research Services & Development Ltd
  • Mertiva AB
  • Mochida Pharmaceutical Co., Ltd.
  • Novartis AG
  • Prometheon Pharma, LLC
  • Sanofi

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • 6860766
  • BVS-857
  • Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis
  • Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders
  • elafibranor
  • englerin A
  • MD-960
  • Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders
  • PEG-Catalase
  • Peptide for Obesity and Insulin Resistance
  • SAR-088
  • SERX-1
  • Small Molecule for Hypertension and Insulin Resistance
  • Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation
  • Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders
  • Small Molecule to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular
  • Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders
  • Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders
  • Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7651IDB

Summary

Global Markets Direct's, 'Insulin Resistance - Pipeline Review, H1 2016', provides an overview of the Insulin Resistance pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Insulin Resistance, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Insulin Resistance
  • The report reviews pipeline therapeutics for Insulin Resistance by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Insulin Resistance therapeutics and enlists all their major and minor projects
  • The report assesses Insulin Resistance therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Insulin Resistance

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Insulin Resistance
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Insulin Resistance Overview
  • Therapeutics Development
    • Pipeline Products for Insulin Resistance - Overview
    • Pipeline Products for Insulin Resistance - Comparative Analysis
  • Insulin Resistance - Therapeutics under Development by Companies
  • Insulin Resistance - Therapeutics under Investigation by Universities/Institutes
  • Insulin Resistance - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Insulin Resistance - Products under Development by Companies
  • Insulin Resistance - Products under Investigation by Universities/Institutes
  • Insulin Resistance - Companies Involved in Therapeutics Development
    • AUS Bio Limited
    • Genentech, Inc.
    • Genfit SA
    • GlaxoSmithKline Plc
    • Hadasit Medical Research Services & Development Ltd
    • Mertiva AB
    • Prometheon Pharma, LLC
    • Sanofi
  • Insulin Resistance - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BFKB-8488A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • elafibranor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • englerin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FC-98 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MD-960 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide for Obesity and Insulin Resistance - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-088 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Hypertension and Insulin Resistance - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SYM-401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Protein Kinase C for Type-2 diabetes and Insulin Resistance - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Insulin Resistance - Recent Pipeline Updates
  • Insulin Resistance - Dormant Projects
  • Insulin Resistance - Product Development Milestones
    • Featured News & Press Releases
      • Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Insulin Resistance, H1 2016
  • Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Insulin Resistance - Pipeline by AUS Bio Limited, H1 2016
  • Insulin Resistance - Pipeline by Genentech, Inc., H1 2016
  • Insulin Resistance - Pipeline by Genfit SA, H1 2016
  • Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016
  • Insulin Resistance - Pipeline by Mertiva AB, H1 2016
  • Insulin Resistance - Pipeline by Prometheon Pharma, LLC, H1 2016
  • Insulin Resistance - Pipeline by Sanofi, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Insulin Resistance Therapeutics - Recent Pipeline Updates, H1 2016
  • Insulin Resistance - Dormant Projects, H1 2016
  • Insulin Resistance - Dormant Projects (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Insulin Resistance, H1 2016
  • Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top